Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over (SARCOLD)

January 28, 2026 updated by: Institut Bergonié

Evaluation of the Impact of Locoregional Treatment of Soft Tissue Sarcoma on the Functional Status of Patients Aged 70 Years and Over

In order to describe functional impact of surgery in elderly patients treated for lower-limb soft-tissue sarcoma, the investigators set up this project which aims to identify prognostic factors among geriatric and functional assessment.

Study Overview

Status

Active, not recruiting

Intervention / Treatment

Detailed Description

This is a prospective cohort including 100 patients > 70 year-old treated by surgery for lower-limb soft-tissue sarcoma. Data on clinical and geriatric characteristics of the patient as well as functional and quality of life assessment will be collected among patient participation (3 years). Primary endpoint is to describe evaluation of the Impact of Locoregional Treatment of Soft Tissue Sarcoma on the Functional Status.

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bordeaux, France, 33076
        • Institut Bergonie

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

70 years and older (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Aged more than 70 years,
  2. Soft tissue sarcoma histologically proven,
  3. Sarcoma of the soft tissues of the lower limbs,
  4. Operable disease (first-line treatment or neo-adjuvant therapy),
  5. ECOG, Performance Status ≤ 2,
  6. Decision of surgery validated in Multidisciplinary Consultation Meeting,
  7. Reports of the non-opposition documented in the patient file before any procedure specific to the study,
  8. Affiliation to system of Social Security (accordance with article L1121-11 of the Code of Public Health).

Exclusion Criteria:

  1. Metastatic disease from the onset or relapse
  2. Participation in another study involving a similar geriatric assessment.
  3. Geographic, familial, social, psychological or psychiatric factors that make the patient incapable of undergoing the study's follow-up and procedures.
  4. Persons deprived of liberty or placed under judicial protection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Prospective cohort
Geriatric assessment
Geriatric assessment, questionnaire assessment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Physical functioning assessment
Time Frame: Change from baseline until 36 months after surgery
Quality of life questionnaire QLQ-C30
Change from baseline until 36 months after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional status assessment (TESS)
Time Frame: Change from baseline until 36 months after surgery
Toronto Extremity salvage score (TESS) Scale
Change from baseline until 36 months after surgery
Functional status assessment (MST)
Time Frame: Change from baseline until 36 months after surgery
Muskuloskeletal Tumor Society (MST) scale
Change from baseline until 36 months after surgery
Quality of life assessment QLQ-C30
Time Frame: Change from baseline until 36 months after surgery
Quality of life questionnaire QLQ-C30
Change from baseline until 36 months after surgery
Quality of life assessment QLQ-EDL-14
Time Frame: Change from baseline until 36 months after surgery
Quality of life questionnaire QLQ-EDL-14
Change from baseline until 36 months after surgery
Geriatric parameters assessment - G8
Time Frame: baseline
G8 (onco-geratic screening score)
baseline
Surgical complications
Time Frame: Change from Day 0 until 12 months after surgery
classification Clavien Dindo
Change from Day 0 until 12 months after surgery
OS
Time Frame: Change from Day 0 until 36 months after surgery
Overall Survival
Change from Day 0 until 36 months after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 30, 2017

Primary Completion (Actual)

January 15, 2023

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

February 20, 2017

First Submitted That Met QC Criteria

March 6, 2017

First Posted (Actual)

March 10, 2017

Study Record Updates

Last Update Posted (Actual)

January 30, 2026

Last Update Submitted That Met QC Criteria

January 28, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Soft Tissue Sarcoma Adult

Clinical Trials on Geriatric assessment

Subscribe